Market Overview

The Saudi Arabia pharmaceuticals market size was valued at USD 9.60 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 11.79 Billion by 2034, exhibiting a growth rate (CAGR) of 2.30% during 2026-2034. Growth is being driven by strategic government efforts under Vision 2030 that are transforming the healthcare sector and localizing pharmaceutical production, alongside a rising incidence of chronic conditions such as diabetes and cardiovascular disease that is lifting demand for prescription therapies. Expanding healthcare infrastructure, growing population demographics, wider health insurance coverage, and strengthened regulatory frameworks are reinforcing this momentum, while government-backed local manufacturing incentives continue to draw technology-transfer investment from global pharmaceutical companies. 

How AI is Reshaping the Future of Saudi Arabia Pharmaceuticals Market:

• AI-assisted drug discovery platforms are helping local and multinational manufacturers shorten formulation timelines, allowing companies expanding production in the Kingdom to bring generics and biosimilars to market faster.
• Predictive analytics tools are being adopted by hospitals and health authorities to forecast chronic disease burden, enabling more accurate procurement planning for cardiovascular, diabetes, and oncology medicines.
• AI-driven supply chain and inventory systems are improving demand forecasting across retail and hospital pharmacy networks, reducing stockouts and strengthening medicine availability nationwide.
• Digital health platforms and AI-enabled telemedicine services are streamlining e-prescriptions, feeding directly into the growing online pharmacy and home-delivery ecosystem.
• Smart manufacturing execution systems are being deployed in new biologics and formulation facilities to maintain quality consistency while scaling up local production volumes.
• AI-powered regulatory and pharmacovigilance tools are helping companies navigate the Saudi Food and Drug Authority's approval pathways more efficiently, supporting faster market access for innovative therapeutics.

Grab a sample PDF of this report:

Market Growth Factors

The rising burden of chronic disease remains a central driver of pharmaceutical demand in the Kingdom. Urbanization and lifestyle shifts are increasing rates of diabetes, hypertension, and cardiovascular conditions, while seasonal pilgrimage inflows add further short-term pressure on medicine consumption. Improved diagnostics and wider screening programs are expanding the treated population, supporting sustained growth in prescriptions, over-the-counter medicines, and long-term therapy adherence across public and private healthcare channels.

Digital commerce is also reshaping market access. High internet penetration and smartphone adoption are fueling growth in licensed online pharmacies and digital health marketplaces, supporting home delivery, repeat prescription fulfilment, and improved reach into remote populations. This is complementing, rather than replacing, the country's extensive retail pharmacy network.

Local manufacturing and industrial policy are accelerating under Vision 2030, with incentives supporting investment in formulation facilities, biotechnology, and vaccine production. In 2025, Pfizer Saudi Arabia and PIF-owned Lifera signed a Memorandum of Understanding at the Global Health Exhibition in Riyadh to explore local drug manufacturing, technology transfer, and workforce development, reflecting the broader push to reduce import reliance and strengthen supply security.

Expansion of biologics manufacturing capacity is adding further momentum, with new high-value production facilities strengthening domestic expertise in complex therapies and positioning Saudi Arabia as a regional pharmaceutical manufacturing base with growing export potential.

We explore the factors propelling the Saudi Arabia pharmaceuticals market growth, including technological advancements, consumer behaviors, and regulatory changes.

Market Segmentation

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the country level. The market has been categorized based on product type, application, distribution channel, and region.

Product Type Insights:

• Prescription Drugs (Branded Drugs, Generic Drugs) — 64% share in 2025
• Over the Counter (OTC) Drugs

Application Insights:

• Cardiovascular Diseases — 30% share in 2025
• Diabetes
• Cancer
• Obesity
• Infectious Diseases
• Others

Distribution Channel Insights:

• Retail Pharmacy — 57% share in 2025
• Hospital Pharmacy
• Online Pharmacy

Regional Insights:

• Northern and Central Region — 38% share in 2025
• Western Region
• Eastern Region
• Southern Region

Key Players:

The market exhibits competitive intensity with multinational corporations and regional manufacturers competing across therapeutic segments. Some of the key players operating in the market include AstraZeneca, GSK plc, Hikma Pharmaceuticals PLC, Jamjoom Pharma, Julphar, Novartis AG, Pfizer Saudi Limited Corporate (Pfizer Inc.), Sanofi KSA (Sanofi S.A.), Saudi Pharmaceutical Industries & Medical Appliances Corporation (SPIMACO), and Tabuk Pharmaceuticals (ASTRA Industrial Group).

Recent Development & News

• October 2025: Lifera, a PIF-owned biopharmaceutical company, announced a potential joint venture with Jamjoom Pharma at the Global Health Exhibition in Riyadh to develop, manufacture, and commercialize vaccines, biologics, and biosimilars within Saudi Arabia, supporting the National Biotechnology Strategy and Vision 2030.
• September 2025: Tabuk Pharmaceutical and Cumberland Pharmaceuticals launched Vibativ® (telavancin), an FDA-approved injectable antibiotic, in Saudi Arabia for treating serious infections, including hospital-acquired pneumonia and drug-resistant skin infections.
• 2025: MS Pharma launched a USD 50 million biologics manufacturing plant in Saudi Arabia to serve both local and international markets, strengthening the Kingdom's biopharmaceutical capabilities and workforce development.
• 2025: The Saudi Food and Drug Authority (SFDA) approved Winrevair (Sotatercept) as an orphan drug for treating pulmonary arterial hypertension in adults, expanding access to advanced therapeutic options.
• 2025: Aster Pharmacy launched its flagship Trio store in Riyadh, introducing drive-through pharmacy services and an integrated health and wellness retail model, with plans to establish up to 180 outlets nationwide.
• 2024: Eisai Co., Ltd. began full operations at its new Saudi Arabian subsidiary, Eisai Pharmaceuticals Single Person LLC, in Riyadh, handling local sales and marketing of its drugs to expand direct market access.

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

About Us

IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA,

Email: [email protected],

Tel No: (D) +91 120 433 0800,

United States: +1-201971-6302